BOPI 11 BR/2023 REPERTOIRE NUMERIQUE 21 (73) UPL LIMITED, UPL House, 610 B/2, Off Western Express Highway, Bandra Village, Bandra-East, Maharashtra, MUMBAI 400051 (IN) (74) S.C.P AKKUM, AKKUM & Associates, n° 1777, Rue 6.261, Auditorium Jean Paul II, Quartier Mbankolo, B.P. 4966, YAOUNDE (CM). (57) The present invention provides a stabilization system for an agrochemical composition comprising at least one steric stabilizer and at least one static stabilizer. The present invention further provides an aqueous insecticidal composition comprising at least one insecticide and said stabilization system. The present invention also discloses process of preparing aqueous insecticidal composition, a method of controlling pests and use of said composition as insecticide. Consulter le mémoire ________________________________________ (11) 21248 (51) A61K 31/13 (2018.01); A61K 31/27 (2018.01); A61K 31/445 (2018.01); A61K 31/47 (2018.01); A61K 31/473 (2018.01); A61K 31/55 (2018.01); A61K 45/06 (2018.01) ; A61P 25/28 (2018.01) (21) 1202300025 - PCT/IB2021/056986 (22) 30/07/2021 (30) IN n° 202021032951 du 31/07/2020 (54) N'-(2-Chloro-6-Methylbenzoyl)-4-Methyl-3- [2-(3-Quinolyl) Ethynyl]-Benzohydrazide for treatment of Alzheimer's disease. (72) DAMLE, Nitin Krishnaji (IN); MANDHANE, Sanjay Nandlalhi (IN); SONI, Durgesh Ashokkumar (IN); JAIN, Shakti Kamalchand (IN) et RAMANATHAN, Vikram Krishna (IN) (73) SUN PHARMA ADVANCED RESEARCH COMPANY LIMITED, 17B, Mahal Industrial Estate, Mahakali Caves Road, Andheri (E), MUMBAI, Maharashtra 400093 (IN) (74) ALEMBONG OSWALD AMIN, S/C Von Seidels Cameroon Sarl, EasyOffice Building, Centre de l'Artisanat, Carrefour Intendance, B.P. 30188, YAOUNDE (CM). (57) The present invention provides a method for preventing or treating Alzheimer's disease and symptoms thereof comprising administering to a subject in need thereof a therapeutically effective amount of N' -(2-chloro-6-methylbenzoyl)-4methyl-3-[2-(3-quinolyl)ethynyl]-benzohydrazide or a its pharmaceutically acceptable salts, wherein the prevention and/or treatment of said disease and symptoms thereof is achieved by inhibition of amyloid-beta (AB) plaque aggregation, tau hyperphosphorylation, c-Abl kinase or a combination thereof. Also disclosed is the use of a therapeutically effective amount of Ar-(2-chloro-6methylbenzoyl)-4-methyl-3-[2-(3-quinolyl)ethynyl]- benzohydrazide or its pharmaceutically acceptable salts to inhibit amyloid-beta (A0) plaque aggregation, tau hyperphosphorylation. cAbl kinase or a combination thereof. Figure 1 Consulter le mémoire
RkJQdWJsaXNoZXIy MTM1NDc3MA==